A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Lung Cancer Non-small Cell Stage IV Clinical Trial

Official title:
A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Pemetrexed vs Placebo Combined With Carboplatin and Pemetrexed as First-line Therapy in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Status Terminated

Clinical Trial Summary

This is a phase III , randomized, double-blinded, multicenter clinical study to compare efficacy and safety of AK105 (Anti-PD1 antibody) combined with Carboplatin and Pemetrexed vs Placebo combined with Carboplatin and Pemetrexed as first-line therapy in patients with EGFR and ALK wild type metastatic nonsquamous non-small cell lung cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Cancer Non-small Cell Stage IV
Lung Neoplasms

Clinical Trial Details

NCT number	NCT03866980
Study type	Interventional
Source	Akeso
Contact
Status	Terminated
Phase	Phase 3
Start date	November 27, 2018
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03692442` - Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
Recruiting	`NCT03769103` - Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC	Phase 2
Completed	`NCT02129699` - Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy	Phase 3
Recruiting	`NCT05127382` - Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer
Completed	`NCT03866993` - A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer	Phase 3
Not yet recruiting	`NCT04184921` - Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients